Transdermal PTEN mRNA Delivery via HA-LNPs for Melanoma Ther
2026-07-09
Transdermal PTEN mRNA Delivery via HA-LNPs: A New Approach for Melanoma Immunotherapy
Study Background and Research Question
Melanoma remains one of the most aggressive forms of skin cancer, characterized by high metastatic potential and limited response rates to current immunotherapies such as immune checkpoint inhibitors (ICIs). Resistance to ICIs is frequently linked to the loss or mutation of the phosphatase and tensin homolog (PTEN) tumor suppressor gene, a critical regulator of the PI3K/Akt signaling pathway. Deficiency in PTEN not only promotes unchecked cell proliferation but also impairs T cell infiltration and cytotoxicity, fueling immune evasion and tumor persistence. The central research question of the recent reference study was whether transdermal delivery of PTEN mRNA could restore tumor suppressor activity, reactivate antitumor immunity, and inhibit melanoma progression.Key Innovation from the Reference Study
The reference paper introduces a novel hyaluronate-conjugated lipid nanoparticle (HA-LNP) system for the non-invasive, transdermal delivery of PTEN mRNA. The core innovation lies in the design of an amphiphilic lipid, HA-dimyristoyl glycerol (HA-DMG), which stably incorporates hyaluronate (HA) into the lipid nanoparticle during self-assembly. This approach eliminates the need for post-formulation surface modification and, crucially, replaces poly(ethylene glycol) (PEG), a common LNP stabilizer associated with immunogenicity and anaphylaxis. By leveraging HA's biocompatibility and affinity for the CD44 receptor—abundantly expressed on skin and tumor cells—the HA-LNP platform enables targeted, efficient, and biocompatible delivery of large mRNA payloads.Methods and Experimental Design Insights
The experimental design involved formulating HA-LNPs containing in vitro transcribed PTEN mRNA, then characterizing their physical properties, mRNA encapsulation efficiency, and ability to penetrate skin models. Key methodological advances included:- Utilization of HA-DMG for direct HA integration into the LNP bilayer, ensuring colloidal stability and uniformity without PEG.
- In vitro assays to assess skin penetration, CD44-targeted uptake, and restoration of PTEN expression in melanoma cell lines.
- Evaluation of immunogenic cell death (ICD) induction and cell viability reduction following treatment with PTEN mRNA@HA-LNP.
- In vivo studies using a melanoma mouse model, involving topical application of PTEN mRNA-loaded HA-LNPs, followed by measurement of tumor penetration, growth inhibition, immune activation, and toxicity.
Core Findings and Why They Matter
The study's main findings are substantial:- HA-LNPs demonstrated efficient encapsulation and protection of large PTEN mRNA molecules, while maintaining stability and uniformity.
- Topically applied PTEN mRNA@HA-LNPs penetrated deeply into the skin and selectively targeted CD44-expressing melanoma cells, as confirmed by in vitro and in vivo imaging.
- Treated melanoma cells exhibited restored PTEN expression, increased apoptosis, and decreased viability, indicating successful functional delivery of the tumor suppressor gene mRNA.
- In vivo, the approach led to significant tumor growth inhibition, enhanced immune cell infiltration, and minimal systemic toxicity according to the reference study.
Comparison with Existing Internal Articles
The reference study's approach is further contextualized by related internal resources. For example, one internal review details similar HA-LNP strategies, emphasizing the importance of PEG-free, CD44-targeted delivery for efficient tumor penetration and immune activation. Meanwhile, protocol guides on EZ Cap™ Human PTEN mRNA elaborate on the practical aspects of mRNA transfection and expression, focusing on the value of Cap 1 structures and poly(A) tails for stability and translation efficiency in cancer research. These articles reinforce the need for robust, reproducible workflows in tumor suppressor gene mRNA research and highlight the translational bridge between nanoparticle engineering and therapeutic gene delivery.Limitations and Transferability
Despite its promising outcomes, the reference study acknowledges certain limitations. While transdermal delivery offers a non-invasive and localized route ideal for skin cancers, its applicability to internal tumors may be limited by tissue penetration constraints. Additionally, the long-term immunological effects of repeated HA-LNP administration and the scalability of HA-DMG synthesis require further investigation. The efficacy in human subjects remains to be established, as current evidence is based on preclinical models. Nonetheless, the platform's modular design suggests potential adaptability to other tumor suppressor gene mRNAs and mRNA-based gene therapy research, pending further optimization.Protocol Parameters
- HA-LNP formulation: Incorporate HA-DMG directly during nanoparticle self-assembly for stable, PEG-free HA display.
- PTEN mRNA encapsulation: Use high-quality, in vitro transcribed PTEN mRNA with Cap 1 structure and poly(A) tail for enhanced translation and stability, as recommended in practical guides.
- Topical application: Apply HA-LNP-mRNA formulation onto the skin surface of melanoma-bearing models; optimize dosing based on tumor size and skin permeability.
- Assessment endpoints: Monitor tumor growth, immune cell infiltration, PTEN expression restoration, and systemic toxicity in both in vitro and in vivo settings.